Procoralan ivabradine: Phase III data

In the double-blind, international Phase III SHIFT trial in 6,558 patients with moderate to severe CHF, poor left-ventricular ejection function and a heart rate

Read the full 242 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE